Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India
- PMID: 26691471
- PMCID: PMC4704646
- DOI: 10.1590/S1517-838246420140564
Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India
Abstract
In this study, we present antifungal susceptibility data of clinical and environmental isolates of Central Indian Cryptococcus neoformans (Serotype A, n = 8 and n = 50 respectively) and Cryptococcus gattii (Serotype B, n = 01 and n = 04 respectively). Susceptibilities to fluconazole, itraconazole and ketoconazole were determined by using NCCLS broth micro-dilution methodology. The total number of resistant strains for fluconazole in case of C. neoformans and C. gattii showed a significant difference by using chi-square test (p < 0.05*), while considering fisher's exact p value was nonsignificant (p > 0.05). However, the total number of resistant strains for itraconazole and ketoconazole was not found statistically significant. A comparison of geometric means of clinical and environmental strains of C. gattii and C. neoformans was not found statistically significant using student 't' test (p value > 0.05 NS). Though less, the antifungal data obtained in this study suggests that primary resistance among environmental and clinical isolates of C. neoformans and C. gattii against tested antifungal was present and C. gattii comparatively was less susceptible than C. neoformans var. grubii isolates to fluconazole than to itraconazole and ketoconazole. A continuous surveillance of antifungal susceptibility of clinical and environmental isolates of C. neoformans and C. gattii is desirable to monitor the emergence of any resistant strains for better management of cryptococcosis patients.
Similar articles
-
In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.J Med Microbiol. 2011 Jul;60(Pt 7):961-967. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10. J Med Microbiol. 2011. PMID: 21393452
-
Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.Med Mycol. 2013 Aug;51(6):635-40. doi: 10.3109/13693786.2012.761737. Epub 2013 Jan 23. Med Mycol. 2013. PMID: 23343452
-
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.Mycoses. 2006 Jul;49(4):324-30. doi: 10.1111/j.1439-0507.2006.01242.x. Mycoses. 2006. PMID: 16784448
-
Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update.Crit Rev Microbiol. 2012 Feb;38(1):1-16. doi: 10.3109/1040841X.2011.606426. Epub 2011 Dec 1. Crit Rev Microbiol. 2012. PMID: 22133016 Review.
-
Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.Med Mycol. 2024 Jun 27;62(6):myae043. doi: 10.1093/mmy/myae043. Med Mycol. 2024. PMID: 38935902 Free PMC article.
Cited by
-
Ecoepidemiology of Cryptococcus gattii in Developing Countries.J Fungi (Basel). 2017 Nov 3;3(4):62. doi: 10.3390/jof3040062. J Fungi (Basel). 2017. PMID: 29371578 Free PMC article. Review.
-
Advanced approach for antifungal susceptibility and characterization of resistance properties in clinical and environmental isolates of Cryptococcus species complex.Infect Med (Beijing). 2022 Aug 29;1(3):147-153. doi: 10.1016/j.imj.2022.08.006. eCollection 2022 Sep. Infect Med (Beijing). 2022. PMID: 38077629 Free PMC article.
-
First Isolation, Antifungal Susceptibility, and Molecular Characterization of Cryptococcus neoformans from the Environment in Croatia.J Fungi (Basel). 2019 Oct 12;5(4):99. doi: 10.3390/jof5040099. J Fungi (Basel). 2019. PMID: 31614885 Free PMC article.
-
Antifungal Resistance in Cryptococcal Infections.Pathogens. 2024 Jan 29;13(2):128. doi: 10.3390/pathogens13020128. Pathogens. 2024. PMID: 38392866 Free PMC article. Review.
-
In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China.Front Microbiol. 2021 Aug 10;12:708280. doi: 10.3389/fmicb.2021.708280. eCollection 2021. Front Microbiol. 2021. PMID: 34447360 Free PMC article.
References
-
- Casadevall A, Perfect JR. Cryptococcus neoformans. Washington DC: American Society for Microbiology; 1998.
-
- Chowdhary A, Randhawa HS, Sundar G, et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol. 2011;60:961–967. - PubMed
-
- Davey KG, Johnson EM, Holmes AD, et al. In vitro susceptibility of C. neoformans isolates to Fluconazole and Itraconazole. Antimicrob Agents Chemother. 1998;42:217–220. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous